10.08.2011 • News

Synthes H1 Profit Rises

Synthes posted higher six-month net earnings of $454.37 million compared with $424.59 million last year. Half-yearly earnings per share improved to €3.83 from €3.58 a year earlier.

Net sales increased to $1.97 billion from $1.80 billion in the comparable period.

First-half 2011 gross profit margin of 82.5% remained strong and was in-line with the previous year of 82.4%, as continued pricing pressures were mitigated by ongoing operational improvements, the company added.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.